Nectin-4
Nectin-4 is a cell adhesion molecule that plays a crucial role in cell-cell adhesion and communication. Nectin-4 is involved in various physiological processes such as embryonic development and tissue homeostasis. Nectin-4 is overexpressed on the surface of tumor cells, making it an attractive target for cancer therapy. Nectin-4 belongs to the nectin family of proteins, which is characterized by immunoglobulin-like domains and plays important roles in mediating cell-cell interactions through homophilic and heterophilic binding[1][2][3].
References:
- [1]. Liu Y, et al. Role of Nectin?4 protein in cancer (Review). Int J Oncol. 2021 Nov;59(5):93. [Content Brief]
- [2]. Heath EI, et al. The biology and rationale of targeting nectin-4 in urothelial carcinoma. Nat Rev Urol. 2021 Feb;18(2):93-103. [Content Brief]
- [3]. Hashimoto H, et al. Nectin-4: a Novel Therapeutic Target for Skin Cancers. Curr Treat Options Oncol. 2022 Apr;23(4):578-593. [Content Brief]
All Product Categories
-
Nectin-4 Related Products (8)
-
Antibodies (1)
-
Enfortumab vedotin-ejfv (solution)
0 ImagesEnfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate (ADC). Enfortumab vedotin-ejfv (solution) is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv (solution) is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma.
-
Enfortumab
0 ImagesEnfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin-ejfv (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma.
-
Enfortumab vedotin-ejfv
0 ImagesEnfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma.
-
Bulumtatug
0 ImagesSynonyms: MW282 mAb
-
Notiretatug
0 ImagesSynonyms: SHR-A2102 antibody
-
NTX-1107C
0 ImagesCat. No.: HY-P992428NST0036 is a human monoclonal antibody against CD112/Nectin-2/PVRL2. NST0036 can be used in cancer research.
-
Sutantatug
0 ImagesSynonyms: SYS6002 Antibody; CRB-701 AntibodySutantatug (SYS6002 Antibody) is a monoclonal antibody targeting Nectin-4, and serves as the antibody moiety of the ADC CRB-701. Sutantatug is applicable to the research of Nectin-4-positive solid tumors, urothelial carcinoma and cervical cancer. The corresponding isotype control for Sutantatug is Human IgG1 kappa, Isotype Control (HY-P99001).
-
BGC1614
0 ImagesCat. No.: HY-178489BGC1614 is a Nectin-4-targeting bicyclic toxin conjugate (BTC) belonging to the category of peptide-drug conjugates (PDCs). BGC1614 exhibits strong targeted binding ability to Nectin-4, with an KD of 3.859 × 10-7 M. BGC1614 exhibits superior antitumor efficacy in nude mice bearing PC-3 and N87 tumor xenografts. BGC1614 can be used for research related to Nectin-4-overexpressing tumors (such as prostate cancer, gastric cancer).
